Result of Annual General Meeting

30 June 2021

LONDON, U.K. AND PLANO, TX, U.S. (30 June 2021). Belluscura plc (AIM: BELL), a leading medical device developer focused on lightweight and portable oxygen
enrichment technology, announces that at its Annual General Meeting held today, 30 June 2021, all the resolutions put to shareholders were passed. Resolutions 1 to 6 were passed
as ordinary resolutions and Resolutions 7 and 8 were passed as special resolutions. The final proxy voting position is shown below.  Any proxy votes which are at the discretion
of the Chairman have been included in the “For” total.

No. Resolutions(Please refer to Notice of Meeting for full text) For Against Vote Withheld % Vote Cast For[1]
Ordinary Resolutions
1. To adopt the audited accounts of the Company for the period ended 31 December 2020. 50,496,815 0 0 100%
2. To re-elect Robert Rauker as a Director of the Company. 50,496,815 0 0 100%
3. To re-elect Anthony Dyer as a Director of the Company. 50,496,815 0 0 100%
4. To re-appointed KPMG LLP as auditor to the Company. 50,495,815 1,000 0 99.998%
5. To authorise the Directors to determine the remuneration of the auditors. 50,495,815 1,000 0 99.998%
6. Authority to Allot Shares. 50,495,815 1,000 0 99.998%
Special Resolutions
7. Disapplication of Statutory Pre-Emption Rights. 49,329,149 1,167,666 0 97.688%
8. Authority to Purchase Own Shares. 50,496,815 0 0 100%

 

For further information please contact:

Belluscura plc www.belluscura.com
Robert Rauker, Chief Executive Officer via Walbrook PR
Anthony Dyer, Chief Financial Officer
SPARK Advisory Partners Limited (NOMAD) Tel: +44 (0)20 3368 3550
Neil Baldwin
Dowgate Capital Limited (Broker) Tel: +44 (0)20 3903 7715
James Serjeant / Nicholas Chambers
Walbrook PR Ltd (Media & Investor Relations) Tel: +44 (0)20 7933 8780 or belluscura@walbrookpr.com
Paul McManus / Sam Allen Mob: +44 (0)7980 541 893 / +44 (0)7502 558 258

About Belluscura plc (www.belluscura.com) Belluscura is a UK medical device company focused on
developing oxygen enrichment technology spanning broad industries and therapies. Our innovative oxygen technologies are designed with a global purpose: to create improved health
and economic outcomes for the patients, healthcare providers and insurance organisations. Belluscura is listed on the AIM market of the London Stock Exchange (AIM: BELL).